| Year |
Citation |
Score |
| 2023 |
Brucato G, Hesson H, Dishy G, Lee K, Pia T, Syed F, Villalobos A, Rogers RT, Corbeil T, Stone MH, Lieberman JA, Appelbaum PS, Girgis RR. An Analysis of Motivating Factors in 1,725 Worldwide Cases of Mass Murder Between 1900-2019. The Journal of Forensic Psychiatry & Psychology. 34: 261-274. PMID 37600153 DOI: 10.1080/14789949.2023.2208570 |
0.338 |
|
| 2023 |
Sehatpour P, Iosifescu DV, De Baun HM, Shope C, Mayer MR, Gangwisch J, Dias E, Sobeih T, Choo TH, Wall MM, Medalia A, Saperstein AM, Kegeles LS, Girgis RR, Carlson M, et al. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine. Biological Psychiatry. PMID 36958998 DOI: 10.1016/j.biopsych.2023.01.015 |
0.311 |
|
| 2022 |
Williams JC, Zheng ZJ, Tubiolo PN, Luceno JR, Gil RB, Girgis RR, Slifstein M, Abi-Dargham A, Van Snellenberg JX. Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients With Schizophrenia. Biological Psychiatry Global Open Science. 3: 990-1002. PMID 37881571 DOI: 10.1016/j.bpsgos.2022.10.003 |
0.609 |
|
| 2022 |
Kohler CG, Wolf DH, Abi-Dargham A, Anticevic A, Cho YT, Fonteneau C, Gil R, Girgis RR, Gray DL, Grinband J, Javitch JA, Kantrowitz JT, Krystal JH, Lieberman JA, Murray JD, et al. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science. 3: 340-350. PMID 37519466 DOI: 10.1016/j.bpsgos.2022.05.009 |
0.569 |
|
| 2022 |
Girgis RR, Rogers RT, Hesson H, Lieberman JA, Appelbaum PS, Brucato G. Mass murders involving firearms and other methods in school, college, and university settings: Findings from the Columbia Mass Murder Database. Journal of Forensic Sciences. PMID 36303265 DOI: 10.1111/1556-4029.15161 |
0.333 |
|
| 2021 |
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, et al. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin. PMID 34423843 DOI: 10.1093/schbul/sbab095 |
0.602 |
|
| 2020 |
Sehatpour P, Avissar M, Kantrowitz JT, Corcoran CM, De Baun HM, Patel GH, Girgis RR, Brucato G, Lopez-Calderon J, Silipo G, Dias E, Martinez A, Javitt DC. Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia. Frontiers in Psychiatry. 11: 629144. PMID 33603682 DOI: 10.3389/fpsyt.2020.629144 |
0.301 |
|
| 2020 |
Girgis RR, Slifstein M, Brucato G, Kegeles LS, Colibazzi T, Lieberman JA, Abi-Dargham A. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [C]-(+)-PHNO PET with methylphenidate challenge study. Molecular Psychiatry. PMID 33154566 DOI: 10.1038/s41380-020-00934-w |
0.61 |
|
| 2019 |
Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D and D and serotonin 5-HT and 5-HT receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 45: 786-792. PMID 31847007 DOI: 10.1038/s41386-019-0590-6 |
0.566 |
|
| 2019 |
Slifstein M, Abi-Dargham A, Girgis RR, Suckow RF, Cooper TB, Divgi CR, Sokoloff P, Leriche L, Carberry P, Oya S, Joseph SK, Guiraud M, Montagne A, Brunner V, Gaudoux F, et al. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [C]-(+)-PHNO. Psychopharmacology. PMID 31773210 DOI: 10.1007/s00213-019-05387-w |
0.608 |
|
| 2019 |
Girgis RR, Baker S, Mao X, Gil R, Javitt DC, Kantrowitz JT, Gu M, Spielman DM, Ojeil N, Xu X, Abi-Dargham A, Shungu DC, Kegeles LS. Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. Psychiatry Research. 275: 78-85. PMID 30884334 DOI: 10.1016/J.Psychres.2019.03.018 |
0.611 |
|
| 2019 |
Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, et al. A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. Neuroimage. Clinical. 22: 101739. PMID 30852397 DOI: 10.1016/J.Nicl.2019.101739 |
0.354 |
|
| 2019 |
Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, Bellei C, Valmadre A, Vanegas N, Kegeles LS, Brucato G, Jung Kang U, Sulzer D, Zecca L, Abi-Dargham A, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proceedings of the National Academy of Sciences of the United States of America. PMID 30796187 DOI: 10.1073/Pnas.1807983116 |
0.585 |
|
| 2018 |
Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of Psychiatric Research. PMID 30055853 DOI: 10.1016/J.Jpsychires.2018.07.006 |
0.375 |
|
| 2017 |
Colibazzi T, Yang Z, Horga G, Chao-Gan Y, Corcoran CM, Klahr K, Brucato G, Girgis R, Abi-Dargham A, Milham MP, Peterson BS. Aberrant Temporal Connectivity in Persons at Clinical High Risk for Psychosis. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2: 696-705. PMID 29202110 DOI: 10.1016/J.Bpsc.2016.12.008 |
0.565 |
|
| 2016 |
Lehembre-Shiah E, Leong W, Brucato G, Abi-Dargham A, Lieberman JA, Horga G, Girgis RR. Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population. Jama Psychiatry. PMID 27851840 DOI: 10.1001/Jamapsychiatry.2016.3055 |
0.487 |
|
| 2016 |
Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. PMID 27525990 DOI: 10.1007/S00213-016-4382-Y |
0.63 |
|
| 2016 |
Van Snellenberg JX, Girgis RR, Horga G, van de Giessen E, Slifstein M, Ojeil N, Weinstein JJ, Moore H, Lieberman JA, Shohamy D, Smith EE, Abi-Dargham A. Mechanisms of Working Memory Impairment in Schizophrenia. Biological Psychiatry. PMID 27056754 DOI: 10.1016/J.Biopsych.2016.02.017 |
0.606 |
|
| 2016 |
Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. Journal of Psychopharmacology (Oxford, England). PMID 26966119 DOI: 10.1177/0269881116636120 |
0.612 |
|
| 2016 |
Arnsten AF, Girgis RR, Gray DL, Mailman RB. Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. Biological Psychiatry. PMID 26946382 DOI: 10.1016/j.biopsych.2015.12.028 |
0.425 |
|
| 2015 |
Colibazzi T, Horga G, Wang Z, Huo Y, Corcoran C, Klahr K, Brucato G, Girgis R, Gill K, Abi-Dargham A, Peterson BS. Neural Dysfunction in Cognitive Control Circuits in Persons at Clinical High-Risk for Psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26354046 DOI: 10.1038/npp.2015.273 |
0.565 |
|
| 2015 |
Girgis RR, Xu X, Gil RB, Hackett E, Ojeil N, Lieberman JA, Slifstein M, Abi-Dargham A. Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [(11)C]-(+)-PHNO. Schizophrenia Research. 168: 373-6. PMID 26190300 DOI: 10.1016/J.Schres.2015.06.027 |
0.595 |
|
| 2015 |
Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. Jama Psychiatry. 72: 316-24. PMID 25651194 DOI: 10.1001/Jamapsychiatry.2014.2414 |
0.633 |
|
| 2015 |
Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 446-53. PMID 25074637 DOI: 10.1038/Npp.2014.192 |
0.605 |
|
| 2014 |
van de Giessen E, Rosell DR, Thompson JL, Xu X, Girgis RR, Ehrlich Y, Slifstein M, Abi-Dargham A, Siever LJ. Serotonin transporter availability in impulsive aggressive personality disordered patients: a PET study with [11C]DASB. Journal of Psychiatric Research. 58: 147-54. PMID 25145808 DOI: 10.1016/j.jpsychires.2014.07.025 |
0.538 |
|
| 2014 |
Thompson JL, Rosell DR, Slifstein M, Girgis RR, Xu X, Ehrlich Y, Kegeles LS, Hazlett EA, Abi-Dargham A, Siever LJ. Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112. Psychopharmacology. 231: 4231-40. PMID 24781514 DOI: 10.1007/s00213-014-3566-6 |
0.642 |
|
| 2014 |
Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biological Psychiatry. 75: 292-9. PMID 24439555 DOI: 10.1016/J.Biopsych.2013.12.002 |
0.305 |
|
| 2014 |
Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophrenia Research. 152: 325-32. PMID 24418122 DOI: 10.1016/J.Schres.2013.12.013 |
0.576 |
|
| 2013 |
Poels EM, Girgis RR, Thompson JL, Slifstein M, Abi-Dargham A. In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia. Psychopharmacology. 228: 167-74. PMID 23460265 DOI: 10.1007/s00213-013-3026-8 |
0.667 |
|
| 2013 |
Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1245-52. PMID 23325325 DOI: 10.1038/Npp.2013.23 |
0.321 |
|
| 2013 |
Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 968-75. PMID 23303043 DOI: 10.1038/Npp.2012.259 |
0.301 |
|
| 2012 |
Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M. Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 1465-73. PMID 22353758 DOI: 10.1038/npp.2011.332 |
0.515 |
|
| 2012 |
Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S, Haney M, Abi-Dargham A. Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biological Psychiatry. 71: 677-83. PMID 22290115 DOI: 10.1016/j.biopsych.2011.12.018 |
0.583 |
|
| 2012 |
Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Archives of General Psychiatry. 69: 449-59. PMID 22213769 DOI: 10.1001/archgenpsychiatry.2011.1519 |
0.58 |
|
| 2011 |
Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E. The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB. Psychiatry Research. 194: 230-4. PMID 22079057 DOI: 10.1016/J.Pscychresns.2011.04.007 |
0.537 |
|
| 2011 |
Miyake N, Skinbjerg M, Easwaramoorthy B, Kumar D, Girgis RR, Xu X, Slifstein M, Abi-Dargham A. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biological Psychiatry. 69: 822-4. PMID 21288506 DOI: 10.1016/j.biopsych.2010.12.023 |
0.51 |
|
| 2011 |
Girgis RR, Xu X, Miyake N, Easwaramoorthy B, Gunn RN, Rabiner EA, Abi-Dargham A, Slifstein M. In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 887-95. PMID 21178982 DOI: 10.1038/Npp.2010.228 |
0.584 |
|
| Show low-probability matches. |